Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.

Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG.

Cancer Res. 2009 Oct 1;69(19):7713-20. doi: 10.1158/0008-5472.CAN-09-1013. Epub 2009 Sep 22.

2.

Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.

Hastie E, Grdzelishvili VZ.

J Gen Virol. 2012 Dec;93(Pt 12):2529-45. doi: 10.1099/vir.0.046672-0. Epub 2012 Oct 10. Review.

3.

Understanding and altering cell tropism of vesicular stomatitis virus.

Hastie E, Cataldi M, Marriott I, Grdzelishvili VZ.

Virus Res. 2013 Sep;176(1-2):16-32. doi: 10.1016/j.virusres.2013.06.003. Epub 2013 Jun 22. Review.

4.

Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.

Heiber JF, Xu XX, Barber GN.

Chin J Cancer. 2011 Dec;30(12):805-14. doi: 10.5732/cjc.011.10205. Epub 2011 Nov 4. Review.

5.

Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".

Melzer MK, Lopez-Martinez A, Altomonte J.

Biomedicines. 2017 Feb 10;5(1). pii: E8. doi: 10.3390/biomedicines5010008. Review.

6.

Oncolytic virotherapy for human malignant mesothelioma: recent advances.

Boisgerault N, Achard C, Delaunay T, Cellerin L, Tangy F, Grégoire M, Fonteneau JF.

Oncolytic Virother. 2015 Sep 10;4:133-40. doi: 10.2147/OV.S66091. eCollection 2015. Review.

7.

Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.

Upham JW, Garlepp MJ, Musk AW, Robinson BW.

Thorax. 1995 Aug;50(8):887-93. Review. No abstract available.

8.

Exploring interferon beta for gene therapy of HIV infection.

Lauret E, Vieillard V, Rousseau V, De Maeyer-Guignard J, De Maeyer E.

Res Immunol. 1994 Oct-Dec;145(8-9):674-7; discussion 677-8. Review. No abstract available.

PMID:
7754218

Supplemental Content

Support Center